Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1;81(7):1453-1468.e12.
doi: 10.1016/j.molcel.2021.01.034. Epub 2021 Mar 3.

Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer

Affiliations
Free article

Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer

Maciej Cieśla et al. Mol Cell. .
Free article

Abstract

Splicing is a central RNA-based process commonly altered in human cancers; however, how spliceosomal components are co-opted during tumorigenesis remains poorly defined. Here we unravel the core splice factor SF3A3 at the nexus of a translation-based program that rewires splicing during malignant transformation. Upon MYC hyperactivation, SF3A3 levels are modulated translationally through an RNA stem-loop in an eIF3D-dependent manner. This ensures accurate splicing of mRNAs enriched for mitochondrial regulators. Altered SF3A3 translation leads to metabolic reprogramming and stem-like properties that fuel MYC tumorigenic potential in vivo. Our analysis reveals that SF3A3 protein levels predict molecular and phenotypic features of aggressive human breast cancers. These findings unveil a post-transcriptional interplay between splicing and translation that governs critical facets of MYC-driven oncogenesis.

Keywords: DRP1; MYC; SF3A3; alternative splicing; cancer plasticity; cancer stem cells; eIF3D; mitochondrial dynamics; translation control; triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.B. received travel grants from Roche and participated in advisory board meetings for Pfizer and Novartis. All other authors declare no competing interests.

Comment in

MeSH terms